Opinion of the Transparency Council – valganciclovir
At its meeting on 10 February 2025, the Transparency Council adopted opinion No.30/2025 on the reimbursement of medicines containing the active substance valganciclovir for indications, dosages or methods of administration other than those specified in the Summary of Product Characteristics, i.e. cytomegalovirus infection in patients undergoing transplantation of a limb, cornea, bone marrow, tissue or cells – prophylaxis after the end of hospitalization related to transplantation up to 110 days after transplantation